The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
DNA Repair in Prostate Cancer: Biology and Clinical Implications
Open accessAbstract
CONTEXT: For more precise, personalized care in prostate cancer (PC), a new classification based on molecular features relevant for prognostication and treatment stratification is needed. Genomic aberrations in the DNA damage repair pathway are common in PC, particularly in late-stage disease, and may be relevant for treatment stratification. OBJECTIVE: To review current knowledge on the prevalence and clinical significance of aberrations in DNA repair genes in PC, particularly in metastatic disease. EVIDENCE ACQUISITION: A literature search up to July 2016 was conducted, including clinical trials and preclinical basic research studies. Keywords included DNA repair, BRCA, ATM, CRPC, prostate cancer, PARP, platinum, predictive biomarkers, and hereditary cancer. EVIDENCE SYNTHESIS: We review how the DNA repair pathway is relevant to prostate carcinogenesis and progression. Data on how this may be relevant to hereditary cancer and genetic counseling are included, as well as data from clinical trials of PARP inhibitors and platinum therapeutics in PC. CONCLUSIONS: Relevant studies have identified genomic defects in DNA repair in PCs in 20-30% of advanced castration-resistant PC cases, a proportion of which are germline aberrations and heritable. Phase 1/2 clinical trial data, and other supporting clinical data, support the development of PARP inhibitors and DNA-damaging agents in this molecularly defined subgroup of PC following success in other cancer types. These studies may be an opportunity to improve patient care with personalized therapeutic strategies. PATIENT SUMMARY: Key literature on how genomic defects in the DNA damage repair pathway are relevant for prostate cancer biology and clinical management is reviewed. Potential implications for future changes in patient care are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Self-citationInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Self-citationLin, C., Yang, L., Tanasa, B., Hutt, K., Ju, B.-G., Ohgi, K. A., Zhang, J., Rose, D. W., Fu, X.-D., Glass, C. K., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.030 · Cited by 576
Research works printed but not linked: 62
- Lorente, 2015, Sequencing of agents in castration-resistant prostate cancer, Lancet Oncol, 16, e279, 10.1016/S1470-2045(15)70033-1 · DOI
- Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 · DOI · Paper page
- Rubin, 2015, Genomic correlates to the newly proposed grading prognostic groups for prostate cancer, Eur Urol, 69, 2
- Baca, 2013, Punctuated evolution of prostate cancer genomes, Cell, 153, 666, 10.1016/j.cell.2013.03.021 · DOI · Paper page
- Barbieri, 2012, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat Genet, 44, 685, 10.1038/ng.2279 · DOI · Paper page
- Berger, 2011, The genomic complexity of primary human prostate cancer, Nature, 470, 214, 10.1038/nature09744 · DOI · Paper page
- Abeshouse, 2015, The molecular taxonomy of primary prostate cancer, Cell, 163, 1011, 10.1016/j.cell.2015.10.025 · DOI · Paper page
- Meeks, 2016, BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers, J Natl Cancer Inst, 108, 10.1093/jnci/djv315 · DOI
- Beltran, 2013, Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity, Eur Urol, 63, 920, 10.1016/j.eururo.2012.08.053 · DOI · Paper page
- Kumar, 2016, Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer, Nat Med, 22, 369, 10.1038/nm.4053 · DOI · Paper page
- Beltran, 2016, Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, Nat Med, 22, 298, 10.1038/nm.4045 · DOI · Paper page
- Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 · DOI · Paper page
- Wood, 2011, Human DNA repair genes, Science, 1284, 241
- Saleh-Gohari, 2005, Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks, Mol Cell Biol, 25, 7158, 10.1128/MCB.25.16.7158-7169.2005 · DOI · Paper page
- Goodwin, 2013, A hormone-DNA repair circuit governs the response to genotoxic insult, Cancer Discov, 3, 1254, 10.1158/2159-8290.CD-13-0108 · DOI · Paper page
- Polkinghorn, 2013, Androgen receptor signaling regulates DNA repair in prostate cancers, Cancer Discov, 3, 1245, 10.1158/2159-8290.CD-13-0172 · DOI · Paper page
- Ju, 2006, A topoisomerase IIβ-mediated dsDNA break required for regulated transcription, Science, 312, 1798, 10.1126/science.1127196 · DOI · Paper page
- Mani, 2010, Induced chromosomal proximity and the genesis of gene fusions in prostate cancer, Science, 326, 2009
- Boysen, 2015, SPOP mutation leads to genomic instability in prostate cancer, Elife, 4, e09207, 10.7554/eLife.09207 · DOI · Paper page
- Pritchard, 2014, Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer, Nat Commun, 5, 4988, 10.1038/ncomms5988 · DOI · Paper page
- Chen, 2001, Defects of DNA mismatch repair in human prostate cancer, Cancer Res, 61, 4112
- Decker, 2016, Biallelic BRCA2 mutations shape the somatic mutational landscape of aggressive prostate tumors, Am J Hum Genet, 98, 1, 10.1016/j.ajhg.2016.03.003 · DOI
- Castro, 2015, High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers, Ann Oncol, 26, 2293, 10.1093/annonc/mdv356 · DOI
- Carter, 1992, Mendelian inheritance of familial prostate cancer, Proc Natl Acad Sci U S A, 89, 3367, 10.1073/pnas.89.8.3367 · DOI · Paper page
- Kote-Jarai, 2011, BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, Br J Cancer, 105, 1230, 10.1038/bjc.2011.383 · DOI · Paper page
- Leongamornlert, 2012, Germline BRCA1 mutations increase prostate cancer risk, Br J Cancer, 106, 1697, 10.1038/bjc.2012.146 · DOI · Paper page
- Eeles, 2014, The genetic epidemiology of prostate cancer and its clinical implications, Nat Rev Urol, 11, 18, 10.1038/nrurol.2013.266 · DOI · Paper page
- Bancroft, 2014, Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study, Eur Urol, 66, 489, 10.1016/j.eururo.2014.01.003 · DOI · Paper page
- Haraldsdottir, 2014, Prostate cancer incidence in males with Lynch syndrome, Genet Med, 16, 553, 10.1038/gim.2013.193 · DOI
- Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882 · DOI · Paper page
- Castro, 2015, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer, Eur Urol, 68, 186, 10.1016/j.eururo.2014.10.022 · DOI · Paper page
- Gallagher, 2012, Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer, BJU Int, 109, 713, 10.1111/j.1464-410X.2011.10292.x · doi:10.1111/j.1464-410x.2011.10292.x
- Gallagher, 2010, Germline BRCA mutations denote a clinicopathologic subset of prostate cancer, Clin Cancer Res, 16, 2115, 10.1158/1078-0432.CCR-09-2871 · DOI · Paper page
- Dobzhansky, 1946, Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura, Genetics, 31, 269, 10.1093/genetics/31.3.269 · DOI · Paper page
- McCabe, 2006, Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition, Cancer Res, 66, 8109, 10.1158/0008-5472.CAN-06-0140 · DOI · Paper page
- Murai, 2014, Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib, Mol Cancer Ther, 13, 433, 10.1158/1535-7163.MCT-13-0803 · DOI · Paper page
- Patel, 2011, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells, Proc Natl Acad Sci U S A, 108, 3406, 10.1073/pnas.1013715108 · DOI · Paper page
- Bryant, 2009, PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination, EMBO J, 28, 2601, 10.1038/emboj.2009.206 · DOI · Paper page
- Murai, 2012, Trapping of PARP1 and PARP2 by clinical PARP inhibitors, Cancer Res., 72, 5588, 10.1158/0008-5472.CAN-12-2753 · DOI · Paper page
- Schiewer, 2012, Dual roles of PARP-1 promote cancer growth and progression, Cancer Discov, 2, 1134, 10.1158/2159-8290.CD-12-0120 · DOI · Paper page
- Brenner, 2011, Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer, Cancer Cell, 19, 664, 10.1016/j.ccr.2011.04.010 · DOI · Paper page
- Kumar, 2010, Nuclear phosphoinositide 3-kinase controls double-strand break DNA repair, Proc Natl Acad Sci U S A, 107, 7491, 10.1073/pnas.0914242107 · DOI · Paper page
- McCabe, 2015, Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM, Cancer Res, 75, 2159, 10.1158/0008-5472.CAN-14-3502 · DOI
- Hussain, 2016, Co-targeting androgen receptor (AR) and DNA repair: a randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/− the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012), J Clin Oncol, 34, 5010, 10.1200/JCO.2016.34.15_suppl.5010 · doi:10.1200/jco.2016.34.15_suppl.5010
- Sandhu, 2013, The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial, Lancet Oncol, 2045, 1
- Ledermann, 2012, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, N Engl J Med, 366, 1382, 10.1056/NEJMoa1105535 · DOI · Paper page
- Tutt, 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial, Lancet, 376, 235, 10.1016/S0140-6736(10)60892-6 · DOI · Paper page
- Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 15, 852, 10.1016/S1470-2045(14)70228-1 · DOI · Paper page
- Audeh, 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial, Lancet, 376, 245, 10.1016/S0140-6736(10)60893-8 · DOI · Paper page
- Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol, 33, 244, 10.1200/JCO.2014.56.2728 · DOI · Paper page
- Fong, 2010, Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval, J Clin Oncol, 28, 2512, 10.1200/JCO.2009.26.9589 · DOI · Paper page
- Shen, 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency, Clin Cancer Res., 19, 5003, 10.1158/1078-0432.CCR-13-1391 · DOI · Paper page
- de Bono, 2013, First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors, J Clin Oncol, 31, 2580, 10.1200/jco.2013.31.15_suppl.2580 · DOI
- Ihnen, 2013, Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer, Mol Cancer Ther, 12, 1002, 10.1158/1535-7163.MCT-12-0813 · DOI
- Hussain, 2014, Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer, Invest New Drugs, 32, 904, 10.1007/s10637-014-0099-0 · DOI
- Mateo, 2016, An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib, Target Oncol, 11, 401, 10.1007/s11523-016-0435-8 · DOI
- Chao, 2014, Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP, Mol Cancer Res, 12, 1755, 10.1158/1541-7786.MCR-14-0173 · DOI
- Sternberg, 2009, Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial, J Clin Oncol, 27, 5431, 10.1200/JCO.2008.20.1228 · DOI · Paper page
- Cheng, 2016, Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer, Eur Urol, 69, 992, 10.1016/j.eururo.2015.11.022 · DOI · Paper page
- Ang, 2013, Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of poly(ADP-ribose) polymerase inhibitor resistance: a multi-institutional study, Clin Cancer Res, 44, 1
- Ceccaldi, 2015, A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance, Cancer Res, 75, 1, 10.1158/0008-5472.CAN-14-2593 · DOI
- Aparicio, 2013, Platinum-based chemotherapy for variant castrate-resistant prostate cancer, Clin Cancer Res, 19, 3621, 10.1158/1078-0432.CCR-12-3791 · DOI · Paper page
Cited by
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationNuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437
Self-citationGenomic Markers in Prostate Cancer Decision Making
Cucchiara, V., Cooperberg, M. R., Dall’Era, M., Lin, D. W., Montorsi, F., Schalken, J. A., & Evans, C. P. (2018) · European Urology · doi:10.1016/j.eururo.2017.10.036 · Cited by 269
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance
Gorodetska, I., Kozeretska, I., & Dubrovska, A. (2019) · Journal of Cancer · doi:10.7150/jca.30410 · Cited by 269
Metadata
- Authors
- Mateo, J., Boysen, G., Barbieri, C. E., Bryant, H. E., Castro, E., Nelson, P. S., Olmos, D., Pritchard, C. C., Rubin, M. A., & de Bono, J. S.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 71
- Issue
- 3
- Pages
- 417-425
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2510940971
- Cited by
- 239
- References
- 11
- FWCI
- 21.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DNA Repair in Prostate Cancer: Biology and Clinical Implications. https://app.cochat.ai/papers/10.1016/j.eururo.2016.08.037
- The paper
- Mateo, J., Boysen, G., Barbieri, C. E., Bryant, H. E., Castro, E., Nelson, P. S., Olmos, D., Pritchard, C. C., Rubin, M. A., & de Bono, J. S. (2017). DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology. https://doi.org/10.1016/j.eururo.2016.08.037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.